Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 205

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Open access
Ansell, Stephen M., Maris, Michael B., Lesokhin, Alexander M., Chen, Robert W., Flinn, Ian W., Sawas, Ahmed, Minden, Mark D., Villa, Diego, Percival, Mary-Elizabeth M., Advani, Anjali S., Foran, James M., Horwitz, Steven M., Mei, Matthew G., Zain, Jasmine, Savage, Kerry J., Querfeld, Christiane, Akilov, Oleg E., Johnson, Lisa D.S., Catalano, Tina, Petrova, Penka S., Uger, Robert A., Sievers, Eric L., Milea, Anca, Roberge, Kathleen, Shou, Yaping, O'Connor, Owen A. · 2021 · Clinical Cancer Research

Abstract

Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (NCT02663518) evaluated the safety and activity of TTI-621 in relapsed/refractory (R/R) hematologic malignancies. Patients and Methods: Patients with R/R lymphoma received escalating weekly intravenous TTI-621 to determine the maximum tolerated dose (MTD). During expansion, patients with various malignancies received weekly single-agent TTI-621 at the MTD; TTI-621 was combined with rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL) or with nivolumab in patients with Hodgkin lymphoma. The primary endpoint was the incidence/severity of adverse events (AEs). Secondary endpoint included overall response rate (ORR). Results: Overall, 164 patients received TTI-621: 18 in escalation and 146 in expansion (rituximab combination, n = 35 and nivolumab combination, n = 4). On the basis of transient grade 4 thrombocytopenia, the MTD was determined as 0.2 mg/kg; 0.1 mg/kg was evaluated in combination cohorts. AEs included infusion-related reactions, thrombocytopenia, chills, and fatigue. Thrombocytopenia (20%, grade ≥3) was reversible between doses and not associated with bleeding. Transient thrombocytopenia that determined the initial MTD may not have been dose limiting. The ORR for all patients was 13%. The ORR was 29% (2/7) for diffuse large B-cell lymphoma (DLBCL) and 25% (8/32) for T-cell NHL (T-NHL) with TTI-621 monotherapy and was 21% (5/24) for DLBCL with TTI-621 plus rituximab. Further dose optimization is ongoing. Conclusions: TTI-621 was well-tolerated and demonstrated activity as monotherapy in patients with R/R B-NHL and T-NHL and combined with rituximab in patients with R/R B-NHL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-3706

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 205

Metadata

Authors
Ansell, S. M., Maris, M. B., Lesokhin, A. M., Chen, R. W., Flinn, I. W., Sawas, A., Minden, M. D., Villa, D., Percival, M.-E. M., Advani, A. S., Foran, J. M., Horwitz, S. M., Mei, M. G., Zain, J., Savage, K. J., Querfeld, C., Akilov, O. E., Johnson, L. D. S., Catalano, T., Petrova, P. S., Uger, R. A., Sievers, E. L., Milea, A., Roberge, K., Shou, Y., & O'Connor, O. A.
Venue
Clinical Cancer Research
Published
2021-01-15
Volume
27
Issue
8
Pages
2190-2199
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3118507153
Cited by
205
References
4
FWCI
10.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-3706
The paper
Ansell, S. M., Maris, M. B., Lesokhin, A. M., Chen, R. W., Flinn, I. W., Sawas, A., Minden, M. D., Villa, D., Percival, M.-E. M., Advani, A. S., Foran, J. M., Horwitz, S. M., Mei, M. G., Zain, J., Savage, K. J., Querfeld, C., Akilov, O. E., Johnson, L. D. S., Catalano, T., . . . O'Connor, O. A. (2021). Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-3706

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.